Free Trial
NASDAQ:NRXS

NeurAxis (NRXS) Stock Price, News & Analysis

NeurAxis logo
$2.97 +0.01 (+0.41%)
As of 10:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About NeurAxis Stock (NASDAQ:NRXS)

Key Stats

Today's Range
$2.92
$3.05
50-Day Range
$1.62
$3.99
52-Week Range
$1.33
$6.20
Volume
19,008 shs
Average Volume
404,755 shs
Market Capitalization
$21.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Receive NRXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter.

NRXS Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
Best Penny Stocks To Research - May 20th
See More Headlines

NRXS Stock Analysis - Frequently Asked Questions

NeurAxis' stock was trading at $2.35 at the beginning of the year. Since then, NRXS shares have increased by 26.5% and is now trading at $2.9720.
View the best growth stocks for 2025 here
.

NeurAxis, Inc. (NASDAQ:NRXS) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.25) earnings per share for the quarter. The firm earned $0.67 million during the quarter.

NeurAxis (NRXS) raised $7 million in an initial public offering on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share.

Top institutional investors of NeurAxis include AIGH Capital Management LLC (0.28%).
View institutional ownership trends
.

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), AMMO (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI).

Company Calendar

Last Earnings
11/12/2024
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NRXS
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.63 million
Net Margins
-492.76%
Pretax Margin
-341.35%

Debt

Sales & Book Value

Annual Sales
$2.93 million
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
-10.96

Miscellaneous

Free Float
6,085,000
Market Cap
$21.36 million
Optionable
Not Optionable
Beta
3.34
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:NRXS) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners